Long 10,040 shares of INBX
Bought 10,040 @ $84.56 avg · $848,977 · 2026-10-14
Form 4: Lappe Mark bought INBX
Lappe Mark (Chief Executive Officer at Inhibrx Biosciences, Inc.) reported an open-market purchase of 10,040 shares of INBX at an average $84.56, roughly $848,977, in a Form 4 filed 2026-10-14.
At post $85.26·Now $72.16-15.4% since postedas of Nov 2, 4:15 PM ET
1d+6.1%
3d+5.4%
1w+15.2%
1m—
3m—
6m—
1y—
Long 5,000 shares of INBX
Bought 5,000 @ $100.00 avg · $500,000 · 2026-09-16
Form 4: Kayyem Jon Faiz bought INBX
Kayyem Jon Faiz (Director at Inhibrx Biosciences, Inc.) reported an open-market purchase of 5,000 shares of INBX at an average $100.00, roughly $500,000, in a Form 4 filed 2026-09-17.
At post $104.73·Now $72.16-31.1% since postedas of Nov 2, 4:15 PM ET
1d+4.4%
3d+4.4%
1w-4.1%
1m-14.2%
3m—
6m—
1y—
Long 2,500 shares of INBX
Bought 2,500 @ $114.65 avg · $286,617 · 2026-09-08
Form 4: FORSYTH DOUGLAS bought INBX
FORSYTH DOUGLAS (Director at Inhibrx Biosciences, Inc.) reported an open-market purchase of 2,500 shares of INBX at an average $114.65, roughly $286,617, in a Form 4 filed 2026-09-08.
At post $114.34·Now $72.16-36.9% since postedas of Nov 2, 4:15 PM ET
1d-1.3%
3d-4.4%
1w-7.6%
1m-18.9%
3m—
6m—
1y—
Long 25,000 shares of INBX
Bought 25,000 @ $105.82 avg · $2,645,399 · 2026-09-08
Form 4: Lappe Mark bought INBX
Lappe Mark (Chief Executive Officer at Inhibrx Biosciences, Inc.) reported an open-market purchase of 25,000 shares of INBX at an average $105.82, roughly $2,645,399, in a Form 4 filed 2026-09-08.
At post $114.34·Now $72.16-36.9% since postedas of Nov 2, 4:15 PM ET
1d-1.3%
3d-4.4%
1w-7.6%
1m-18.9%
3m—
6m—
1y—